Act One

Act Two

Act Three

Act Four

Early onset colorectal cancer is bowel cancer diagnosed before the age of 50. It makes up about 10 to 15% of colorectal cancers, and incidence is rising by about 2% a year according to colorectal surgeon Dr Scott Mackenzie. In Episode 113, a patient, a colorectal surgeon and a GI pathologist look at what the condition means for clinicians.

Age is no guide. Many of these patients have few symptoms and present at stage three or four. Helen Worthington describes her diagnosis of stage four bowel cancer at 39 and what she would like doctors to know. Dr Mackenzie explains why persistent bowel symptoms and rectal bleeding need investigation at any age, and why family history is the most practical risk marker. Dr Tristan Rutland covers how these tumours differ under the microscope, including the poorly differentiated, mucinous and signet ring types seen more often in younger patients.

Younger patients are easy to reassure. The guests suggest a low threshold for colonoscopy referral when a younger patient has a persistent change in bowel habit or rectal bleeding, and genetic assessment after any early onset diagnosis. The episode introduces you to the symptoms, risk markers and pathology findings relevant to this group, so you can feel more prepared for the younger patient with bowel symptoms.

This is the story of early onset colorectal cancer.

Our Special Guests:

Helen Worthington is an Adelaide-based primary educator, wife and mum with almost 20 years in schools as a classroom teacher and in leadership roles. In 2025, at 39, she was diagnosed with stage four bowel cancer. She is on extended leave from teaching and having chemotherapy.

Dr Scott Mackenzie studied medicine in Aberdeen, completed basic surgical training in Glasgow, then subspecialty training in general and colorectal surgery in Edinburgh. He was the international colorectal fellow at Concord Hospital in Sydney, and is now a senior lecturer in surgery and a surgeon in the Colorectal Surgery Department at Liverpool Hospital. Scott is a returning guest.

Dr Tristan Rutland is an anatomical pathologist and associate professor at the University of Western Australia, with a subspecialty and research interest in GI pathology and asbestos-related diseases. He received the Conrad Muller RCPA Outstanding Teaching Award in 2020 and the Resident Advocate Award from the College of American Pathologists in 2022. Tristan is a regular guest.

Listen:

This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page.

Early onset colorectal cancer is bowel cancer diagnosed before the age of 50. It makes up about 10 to 15% of colorectal cancers, and incidence is rising by about 2% a year according to colorectal surgeon Dr Scott Mackenzie. In Episode 113, a patient, a colorectal surgeon and a GI pathologist look at what the condition means for clinicians.
Age is no guide. Many of these patients have few symptoms and present at stage three or four. Helen Worthington describes her diagnosis of stage four bowel cancer at 39 and what she would like doctors to know. Dr Mackenzie explains why persistent bowel symptoms and rectal bleeding need investigation at any age, and why family history is the most practical risk marker. Dr Tristan Rutland covers how these tumours differ under the microscope, including the poorly differentiated, mucinous and signet ring types seen more often in younger patients.
Younger patients are easy to reassure. The guests suggest a low threshold for colonoscopy referral when a younger patient has a persistent change in bowel habit or rectal bleeding, and genetic assessment after any early onset diagnosis. The episode introduces you to the symptoms, risk markers and pathology findings relevant to this group, so you can feel more prepared for the younger patient with bowel symptoms.
This is the story of early onset colorectal cancer.
Our Special Guests:
Helen Worthington is an Adelaide-based primary educator, wife and mum with almost 20 years in schools as a classroom teacher and in leadership roles. In 2025, at 39, she was diagnosed with stage four bowel cancer. She is on extended leave from teaching and having chemotherapy.
Dr Scott Mackenzie studied medicine in Aberdeen, completed basic surgical training in Glasgow, then subspecialty training in general and colorectal surgery in Edinburgh. He was the international colorectal fellow at Concord Hospital in Sydney, and is now a senior lecturer in surgery and a surgeon in the Colorectal Surgery Department at Liverpool Hospital. Scott is a returning guest.
Dr Tristan Rutland is an anatomical pathologist and associate professor at the University of Western Australia, with a subspecialty and research interest in GI pathology and asbestos-related diseases. He received the Conrad Muller RCPA Outstanding Teaching Award in 2020 and the Resident Advocate Award from the College of American Pathologists in 2022. Tristan is a regular guest.
Listen:
This Medical Life podcast is available on all podcasting services, <a href="https://podcasts.apple.com/us/podcast/this-medical-life/id1601195297">Apple Podcasts</a>, <a href="https://www.youtube.com/channel/UCOxm-I73JjiBowEMp6JWxSA">YouTube</a>, and <a href="https://open.spotify.com/show/6K8MFiahgDLbYg5uelXS2w">Spotify</a>. Members of the RACGP are able to log the hours as <a href="https://thismedicallife.com.au/cpd-hours/" data-type="page" data-id="437">CPD (Education)</a> that they listen to the episodes under self record via Quick log.&nbsp;<a href="https://thismedicallife.com.au/buy/donation">We invite you to help support us on our donation page</a>.

Early onset colorectal cancer is rising in people under 50. Hear a patient, a colorectal surgeon and a GI pathologist on symptoms and referral.

Episode 113: Early Onset Colorectal Cancer (EOCRC)

Pleomorphic adenoma is the most common parotid gland tumour. It is benign, usually presents as a painless, slow-growing lump near the jaw, and was first described by surgeon Theodor Billroth in 1859. In Episode 112, ENT surgeon Dr Rowan Valentine explains how it is assessed and managed.

Meet the mixed tumour. In 1859, German-born Austrian surgeon Theodor Billroth gave the first medical description of a slow-growing, painless, encapsulated tumour that occurs mainly in the parotid gland, beside the jaw. Under the microscope it showed a mix of tissue types, so he called it a “mixed tumour”. Today we know it as a pleomorphic adenoma.

Billroth also performed the first laryngectomy and the first successful partial gastrectomy for gastric cancer, and he was a friend of the composer Johannes Brahms. Dr Travis Brown tells his story at the start of the episode.

Jaw lumps raise worry. Dr Valentine walks through what he asks, what he examines, and what he recommends when a patient presents with a parotid lump.
History: how long the lump has been there, whether it hurts, whether it changes in size, and whether the patient has noticed any weakness of the face.
Examination: mobility of the lump, the overlying skin, tenderness, sensation near the ear, and the function of each branch of the facial nerve.
Red flags: pain, skin involvement, a history of skin cancer excisions on the head and neck, and facial nerve paralysis.
Biopsy limits: in Dr Valentine’s words, fine needle aspirates and core biopsies have about 90% accuracy in separating benign from cancerous lumps.
Surgery: what the operation involves, how the facial nerve is protected, and the risks Dr Valentine quotes to patients.
Follow-up: why recurrence can follow if the capsule of the tumour is breached, and how that shapes surveillance.

Long-standing lumps are easy to set aside. Dr Valentine explains why a lump that has been present for years still deserves a plan, and his closing advice for doctors is that a parotid lump is cancerous until proven otherwise. The episode introduces you to the questions, examination findings and red flags an ENT surgeon looks for, so you can feel more prepared for the patient who says, “I’ve had this for years.”

This is the story of pleomorphic adenomas.

Our Special Guest:

Dr Rowan Valentine is an adult and paediatric ear, nose and throat (ENT) surgeon. He trained in Adelaide, completed a PhD during his surgical training, and spent a year at the University of Florida on an anatomy fellowship. He supervises surgical trainees and medical students, and he is a regular guest on This Medical Life.

Listen:

This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page.

Pleomorphic adenoma is the most common parotid gland tumour. It is benign, usually presents as a painless, slow-growing lump near the jaw, and was first described by surgeon Theodor Billroth in 1859. In Episode 112, ENT surgeon Dr Rowan Valentine explains how it is assessed and managed.
Meet the mixed tumour. In 1859, German-born Austrian surgeon Theodor Billroth gave the first medical description of a slow-growing, painless, encapsulated tumour that occurs mainly in the parotid gland, beside the jaw. Under the microscope it showed a mix of tissue types, so he called it a &ldquo;mixed tumour&rdquo;. Today we know it as a pleomorphic adenoma.
Billroth also performed the first laryngectomy and the first successful partial gastrectomy for gastric cancer, and he was a friend of the composer Johannes Brahms. Dr Travis Brown tells his story at the start of the episode.
Jaw lumps raise worry. Dr Valentine walks through what he asks, what he examines, and what he recommends when a patient presents with a parotid lump.
<ul>
<li>History: how long the lump has been there, whether it hurts, whether it changes in size, and whether the patient has noticed any weakness of the face.</li>
<li>Examination: mobility of the lump, the overlying skin, tenderness, sensation near the ear, and the function of each branch of the facial nerve.</li>
<li>Red flags: pain, skin involvement, a history of skin cancer excisions on the head and neck, and facial nerve paralysis.</li>
<li>Biopsy limits: in Dr Valentine&rsquo;s words, fine needle aspirates and core biopsies have about 90% accuracy in separating benign from cancerous lumps.</li>
<li>Surgery: what the operation involves, how the facial nerve is protected, and the risks Dr Valentine quotes to patients.</li>
<li>Follow-up: why recurrence can follow if the capsule of the tumour is breached, and how that shapes surveillance.</li>
</ul>
Long-standing lumps are easy to set aside. Dr Valentine explains why a lump that has been present for years still deserves a plan, and his closing advice for doctors is that a parotid lump is cancerous until proven otherwise. The episode introduces you to the questions, examination findings and red flags an ENT surgeon looks for, so you can feel more prepared for the patient who says, &ldquo;I&rsquo;ve had this for years.&rdquo;
This is the story of pleomorphic adenomas.
Our Special Guest:
Dr Rowan Valentine is an adult and paediatric ear, nose and throat (ENT) surgeon. He trained in Adelaide, completed a PhD during his surgical training, and spent a year at the University of Florida on an anatomy fellowship. He supervises surgical trainees and medical students, and he is a regular guest on This Medical Life.
Listen:
This Medical Life podcast is available on all podcasting services, <a href="https://podcasts.apple.com/us/podcast/this-medical-life/id1601195297">Apple Podcasts</a>, <a href="https://www.youtube.com/channel/UCOxm-I73JjiBowEMp6JWxSA">YouTube</a>, and <a href="https://open.spotify.com/show/6K8MFiahgDLbYg5uelXS2w">Spotify</a>. Members of the RACGP are able to log the hours as <a href="https://thismedicallife.com.au/cpd-hours/" data-type="page" data-id="437">CPD (Education)</a> that they listen to the episodes under self record via Quick log.&nbsp;<a href="https://thismedicallife.com.au/buy/donation">We invite you to help support us on our donation page</a>.

Pleomorphic adenoma is the most common parotid tumour. ENT surgeon Dr Rowan Valentine covers assessment, red flags and surgery in Episode 112.

Episode 112: Pleomorphic Adenoma | Mixed Tumours

New guidelines are here. The Prostate Cancer Foundation of Australia and the Australian Government Department of Health, Disability and Ageing have released the 2026 Guidelines for the Early Detection of Prostate Cancer. One in seven Australian men will be diagnosed with prostate cancer. The aim is to find early prostate cancer in the men most at risk, while sparing low-risk men tests they do not need.

The story starts in forensic science. In the 1960s, crime labs needed a better way to detect semen than finding sperm, which break down within minutes to an hour. Dr Travis Brown explains how the Japanese forensic scientist Mitsuhara identified a protein he called gamma-seminoprotein. Teams at Cornell and the University of California found the same protein under other names. Today we call it PSA. By the 1970s, researchers saw it was raised in advanced prostate cancer, and its long, debated path as a screening test began.

The last guidelines came out in 2016. Since then, two things have shifted the balance of risk and benefit: access to multiparametric MRI, and the move from transrectal to transperineal biopsy. In this episode, Ken walks through the key changes:
Free-to-total PSA ratio is no longer needed. MRI is better at sorting risk. About 80% of men with a confirmed PSA above 3 already have a free-to-total ratio below 25%.
Ages 45 to 49 (higher risk): refer when PSA is above 1 ng/mL. This group includes men with a brother with prostate cancer, a father diagnosed at 65 or younger, or a BRCA mutation.
Ages 50 to 69: the threshold stays at 3 ng/mL, or 2 ng/mL for higher-risk men.
Ages 70 and over: for men likely to live more than seven years, the threshold is 5.5 ng/mL. Men below 5.5 can reasonably stop testing.
Repeat the test in one to three months. About 30% of men with a PSA above 3 will test well below 3 on repeat, often due to BPH-related variation.
GPs should now start the conversation. The 2016 guidelines had GPs respond when a man raised it. The new guidelines, endorsed by the RACGP, ask GPs to raise PSA testing with men aged 50 to 69.

Not for prostate cancer screening. In the evidence, rectal exams by non-specialists added as many false positives as false negatives. Ken notes that urologists still gain useful information from it, and a rectal exam remains relevant when you are looking for rectal cancer.

Men with a first-degree relative with prostate cancer, men with BRCA mutations, and men of African ancestry. The guidelines also name Aboriginal and Torres Strait Islander men as a priority population because of poorer access to care. Ken adds that men in regional Victoria have worse prostate cancer outcomes than men in the city.

This is the story of the 2026 Early Detection of Prostate Cancer.

Useful Link:

2026 Guidelines for the Early Detection of Prostate Cancer in Australia

Our Special Guest:

Professor Ken Sikaris is a chemical pathologist and head of clinical integration at Dorevitch Pathology. He is a NATA laboratory assessor, a founding fellow of the RCPA Faculty of Science and a principal examiner in pathology informatics. Ken was one of the first people to measure PSA in Australia, bringing in some of the first test kits around 1989. He helped write the new guidelines.

Listen:

This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page.

New guidelines are here. The Prostate Cancer Foundation of Australia and the Australian Government Department of Health, Disability and Ageing have released the 2026 Guidelines for the Early Detection of Prostate Cancer. One in seven Australian men will be diagnosed with prostate cancer. The aim is to find early prostate cancer in the men most at risk, while sparing low-risk men tests they do not need.
The story starts in forensic science. In the 1960s, crime labs needed a better way to detect semen than finding sperm, which break down within minutes to an hour. Dr Travis Brown explains how the Japanese forensic scientist Mitsuhara identified a protein he called gamma-seminoprotein. Teams at Cornell and the University of California found the same protein under other names. Today we call it PSA. By the 1970s, researchers saw it was raised in advanced prostate cancer, and its long, debated path as a screening test began.
The last guidelines came out in 2016. Since then, two things have shifted the balance of risk and benefit: access to multiparametric MRI, and the move from transrectal to transperineal biopsy. In this episode, Ken walks through the key changes:
<ul>
<li>Free-to-total PSA ratio is no longer needed. MRI is better at sorting risk. About 80% of men with a confirmed PSA above 3 already have a free-to-total ratio below 25%.</li>
<li>Ages 45 to 49 (higher risk): refer when PSA is above 1 ng/mL. This group includes men with a brother with prostate cancer, a father diagnosed at 65 or younger, or a BRCA mutation.</li>
<li>Ages 50 to 69: the threshold stays at 3 ng/mL, or 2 ng/mL for higher-risk men.</li>
<li>Ages 70 and over: for men likely to live more than seven years, the threshold is 5.5 ng/mL. Men below 5.5 can reasonably stop testing.</li>
<li>Repeat the test in one to three months. About 30% of men with a PSA above 3 will test well below 3 on repeat, often due to BPH-related variation.</li>
<li>GPs should now start the conversation. The 2016 guidelines had GPs respond when a man raised it. The new guidelines, endorsed by the RACGP, ask GPs to raise PSA testing with men aged 50 to 69.</li>
</ul>
Not for prostate cancer screening. In the evidence, rectal exams by non-specialists added as many false positives as false negatives. Ken notes that urologists still gain useful information from it, and a rectal exam remains relevant when you are looking for rectal cancer.
Men with a first-degree relative with prostate cancer, men with BRCA mutations, and men of African ancestry. The guidelines also name Aboriginal and Torres Strait Islander men as a priority population because of poorer access to care. Ken adds that men in regional Victoria have worse prostate cancer outcomes than men in the city.
This is the story of the 2026 Early Detection of Prostate Cancer.
Useful Link:
<a href="https://www.pcfa.org.au/awareness/new-guidelines-for-the-early-detection-of-prostate-cancer/">2026 Guidelines for the Early Detection of Prostate Cancer in Australia</a>
Our Special Guest:
Professor Ken Sikaris is a chemical pathologist and head of clinical integration at Dorevitch Pathology. He is a NATA laboratory assessor, a founding fellow of the RCPA Faculty of Science and a principal examiner in pathology informatics. Ken was one of the first people to measure PSA in Australia, bringing in some of the first test kits around 1989. He helped write the new guidelines.
Listen:
This Medical Life podcast is available on all podcasting services, <a href="https://podcasts.apple.com/us/podcast/this-medical-life/id1601195297">Apple Podcasts</a>, <a href="https://www.youtube.com/channel/UCOxm-I73JjiBowEMp6JWxSA">YouTube</a>, and <a href="https://open.spotify.com/show/6K8MFiahgDLbYg5uelXS2w">Spotify</a>. Members of the RACGP are able to log the hours as <a href="https://thismedicallife.com.au/cpd-hours/" data-type="page" data-id="437">CPD (Education)</a> that they listen to the episodes under self record via Quick log.&nbsp;<a href="https://thismedicallife.com.au/buy/donation">We invite you to help support us on our donation page</a>.

Professor Ken Sikaris explains the 2026 Australian prostate cancer early detection guidelines: new PSA thresholds by age, MRI's role and why free PSA is gone.

Episode 111: 2026 Early Prostate Cancer Detection | PSA And mpMRI

In 1880, a French physician described a patient having up to 200 sleep attacks a day, some triggered by nothing more than a good hand of cards or the sight of his own wine barrels. That case, and an earlier 1877 description from German psychiatrist Carl Westphal, gave the condition its name and its first clinical picture. Dr Travis Brown reads from both original case reports before turning to two guests for where narcolepsy stands today.

Di Spillaine, an Australian narcolepsy advocate and lived experience educator, describes going almost 40 years undiagnosed, mistaking her symptoms (childhood hallucinations, cataplexy triggered by laughter, sleep paralysis) for ordinary tiredness until a multiple sleep latency test finally confirmed narcolepsy. Professor Robert Adams, a respiratory and sleep physician at Flinders Medical Centre and medical director of the Adelaide Institute for Sleep Health, explains the underlying orexin deficiency behind narcolepsy type 1, how it differs from everyday tiredness and other sleep disorders, and the diagnostic pathway, including the Epworth Sleepiness Scale and multiple sleep latency testing.

What to listen for: the questions Professor Adams suggests a GP ask beyond “are you tired”, and why narcolepsy sits, in his words, at the end of the queue of likely causes but should still be considered in young patients with long-standing, profound sleepiness.

This is the story of narcolepsy.

Useful Link:

Epworth sleepiness scale: https://www.cdc.gov/niosh/work-hour-training-for-nurses/02/epworth.pdf

Our Special Guests:

Di Spillaine is an Australian narcolepsy advocate, lived experience educator and creator of the podcast Waking Up Tired: Narcolepsy Symptoms Explained

Professor Robert Adams is a respiratory and sleep physician at Flinders Medical Centre and medical director of the Adelaide Institute for Sleep Health at Flinders University

Listen:

This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page.

In 1880, a French physician described a patient having up to 200 sleep attacks a day, some triggered by nothing more than a good hand of cards or the sight of his own wine barrels. That case, and an earlier 1877 description from German psychiatrist Carl Westphal, gave the condition its name and its first clinical picture. Dr Travis Brown reads from both original case reports before turning to two guests for where narcolepsy stands today.
Di Spillaine, an Australian narcolepsy advocate and lived experience educator, describes going almost 40 years undiagnosed, mistaking her symptoms (childhood hallucinations, cataplexy triggered by laughter, sleep paralysis) for ordinary tiredness until a multiple sleep latency test finally confirmed narcolepsy. Professor Robert Adams, a respiratory and sleep physician at Flinders Medical Centre and medical director of the Adelaide Institute for Sleep Health, explains the underlying orexin deficiency behind narcolepsy type 1, how it differs from everyday tiredness and other sleep disorders, and the diagnostic pathway, including the Epworth Sleepiness Scale and multiple sleep latency testing.
What to listen for:&nbsp;the questions Professor Adams suggests a GP ask beyond &ldquo;are you tired&rdquo;, and why narcolepsy sits, in his words, at the end of the queue of likely causes but should still be considered in young patients with long-standing, profound sleepiness.
This is the story of narcolepsy.
Useful Link:
Epworth sleepiness scale:&nbsp;<a href="https://www.cdc.gov/niosh/work-hour-training-for-nurses/02/epworth.pdf">https://www.cdc.gov/niosh/work-hour-training-for-nurses/02/epworth.pdf</a>
Our Special Guests:
Di Spillaine is an Australian narcolepsy advocate, lived experience educator and creator of the podcast&nbsp;<a href="https://podcasts.apple.com/au/podcast/waking-up-tired-narcolepsy-symptoms-explained/id1839149512">Waking Up Tired: Narcolepsy Symptoms Explained</a>
Professor Robert Adams is a respiratory and sleep physician at Flinders Medical Centre and medical director of the&nbsp;<a href="https://www.flinders.edu.au/fhmri/research/sleep-health">Adelaide Institute for Sleep Health at Flinders University</a>
Listen:
This Medical Life podcast is available on all podcasting services,&nbsp;<a href="https://podcasts.apple.com/us/podcast/this-medical-life/id1601195297">Apple Podcasts</a>,&nbsp;<a href="https://www.youtube.com/channel/UCOxm-I73JjiBowEMp6JWxSA">YouTube</a>, and&nbsp;<a href="https://open.spotify.com/show/6K8MFiahgDLbYg5uelXS2w">Spotify</a>. Members of the RACGP are able to log the hours as&nbsp;<a href="https://thismedicallife.com.au/cpd-hours/" data-type="page" data-id="437">CPD (Education)</a>&nbsp;that they listen to the episodes under self record via Quick log.&nbsp;<a href="https://thismedicallife.com.au/buy/donation">We invite you to help support us on our donation page</a>.

A patient with 200 sleep attacks a day helped define narcolepsy in 1880. Di Spillaine and Professor Robert Adams on symptoms, diagnosis and treatment today.

Episode 110: Narcolepsy | Fighting The Sleep Demon

Chapter Three

Sexual harassment in medicine is almost universally perpetrated by men, and in over half of doctor-on-doctor cases, it happens in the workplace itself, not at a conference or a staff event. That is one of the findings from a decade of research by Dr Louise Stone, who began this work in 2014 after a young intern disclosed a sexual assault to her in consultation.

Dr Travis Brown speaks with Dr Louise Stone, a professor of general practice with expertise in doctors’ health, sexual safety and professionalism, about what her research uncovered.

Dr Stone identifies two distinct groups of perpetrators: persistent predators who choose careers with access to power, and a smaller group of senior doctors, often isolated by decades of on-call work, who form inappropriate attachments without the same pattern of repeat behaviour. She explains why junior doctors on rotating three-month terms are especially vulnerable, why specialties such as surgery, psychiatry and pathology carry disproportionate risk, and why zero tolerance policies tend to drive the problem underground rather than reduce it. She also sets out what she has found does help: peer intervention from someone at the same level of seniority as the person behaving badly, and giving survivors clarity on what they actually want from a reporting process, whether that is justice, protection of others, or simply healing.

What to listen for: The early warning signs Dr Stone flags for junior doctors and medical students, and why a colleague’s discomfort is worth naming rather than dismissing.

This is the story about sexual harassment in medicine.

Our Special Guest:

Dr Louise Stone is a professor of general practice, previous lead medical educator for GP training in Australia, and author of Sexual Harassment Between Doctors: Healing Medical Cultures Around the World, available from her website: https://www.drlouisestone.com

Listen:

This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page.

Sexual harassment in medicine is almost universally perpetrated by men, and in over half of doctor-on-doctor cases, it happens in the workplace itself, not at a conference or a staff event. That is one of the findings from a decade of research by Dr Louise Stone, who began this work in 2014 after a young intern disclosed a sexual assault to her in consultation.
Dr Travis Brown speaks with Dr Louise Stone, a professor of general practice with expertise in doctors&rsquo; health, sexual safety and professionalism, about what her research uncovered.
Dr Stone identifies two distinct groups of perpetrators: persistent predators who choose careers with access to power, and a smaller group of senior doctors, often isolated by decades of on-call work, who form inappropriate attachments without the same pattern of repeat behaviour. She explains why junior doctors on rotating three-month terms are especially vulnerable, why specialties such as surgery, psychiatry and pathology carry disproportionate risk, and why zero tolerance policies tend to drive the problem underground rather than reduce it. She also sets out what she has found does help: peer intervention from someone at the same level of seniority as the person behaving badly, and giving survivors clarity on what they actually want from a reporting process, whether that is justice, protection of others, or simply healing.
What to listen for:&nbsp;The early warning signs Dr Stone flags for junior doctors and medical students, and why a colleague&rsquo;s discomfort is worth naming rather than dismissing.
This is the story about sexual harassment in medicine.
Our Special Guest:
Dr Louise Stone is a professor of general practice, previous lead medical educator for GP training in Australia, and author of&nbsp;<a href="https://link.amazon/B0aQCO38c">Sexual Harassment Between Doctors: Healing Medical Cultures Around the World</a>, available from her website:&nbsp;<a href="https://www.drlouisestone.com/">https://www.drlouisestone.com</a>
Listen:
This Medical Life podcast is available on all podcasting services,&nbsp;<a href="https://podcasts.apple.com/us/podcast/this-medical-life/id1601195297">Apple Podcasts</a>,&nbsp;<a href="https://www.youtube.com/channel/UCOxm-I73JjiBowEMp6JWxSA">YouTube</a>, and&nbsp;<a href="https://open.spotify.com/show/6K8MFiahgDLbYg5uelXS2w">Spotify</a>. Members of the RACGP are able to log the hours as&nbsp;<a href="https://thismedicallife.com.au/cpd-hours/" data-type="page" data-id="437">CPD (Education)</a>&nbsp;that they listen to the episodes under self record via Quick log.&nbsp;<a href="https://thismedicallife.com.au/buy/donation">We invite you to help support us on our donation page</a>.

Dr Louise Stone on a decade of research into sexual harassment in medicine, why it persists, and what actually helps a colleague or trainee.

Episode 109: Sexual Harassment In Medicine | Dr Louise Stone

One doctor’s case from 1901 changed how we understand memory loss. Auguste Deter was 51 when her husband Carl brought her to see Dr Alois Alzheimer in Frankfurt, worried by memory lapses that had turned into paranoia and confusion. When Auguste died five years later, Alzheimer examined her brain and found two things under the microscope: amyloid plaques between nerve cells and neurofibrillary tangles within them. His 1906 presentation to a room of psychiatrists drew no questions at all. It was not until 1910, when Emil Kraepelin included the case in his Handbook of Psychiatry, that the term Alzheimer’s disease appeared in print for the first time.

Dr Liam Mulcahy, physician trainee and author of Beyond the White Coat, traces that discovery in detail, then Dr Travis Brown turns to two guests for where the disease stands in 2026.

Dr Daniel Clarke, consultant neurologist at Sir Charles Gairdner Hospital and director of clinical trials at Alzheimer’s Research Australia, covers how Alzheimer’s actually presents (often nothing like the stereotype), why history remains the most important diagnostic tool, and why non-pharmacological measures such as exercise and vascular risk control come before medication. He also explains why family history is often overrated, and why he does not recommend routine APOE4 gene testing.

Dr Gemma Daley, consultant chemical pathologist at Sullivan Nicolaides Pathology, explains what the new p-tau181 and p-tau217 blood tests can and cannot tell a GP, who should and should not be referred for them, and why they are adjunctive tests rather than standalone diagnostic tools.

What to listen for: the presenting features that separate Alzheimer’s from ordinary age-related forgetfulness, and what a negative or positive p-tau result actually means for a patient in front of you.

This is the story of Alzheimer’s disease.

Useful links:

Dementia Australia: https://www.dementia.org.au/

Alzheimer’s Research Australia: https://alzheimersresearch.org.au/

Our Special Guests:

Dr Liam Mulcahy is a physician trainee with an interest in neurology and author of Beyond the White Coat

Dr Daniel Clarke is a consultant neurologist and director of clinical trials at Alzheimer’s Research Australia

Dr Gemma Daley is a consultant chemical pathologist at Sullivan Nicolaides Pathology

Listen:

This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page.

One doctor&rsquo;s case from 1901 changed how we understand memory loss. Auguste Deter was 51 when her husband Carl brought her to see Dr Alois Alzheimer in Frankfurt, worried by memory lapses that had turned into paranoia and confusion. When Auguste died five years later, Alzheimer examined her brain and found two things under the microscope: amyloid plaques between nerve cells and neurofibrillary tangles within them. His 1906 presentation to a room of psychiatrists drew no questions at all. It was not until 1910, when Emil Kraepelin included the case in his Handbook of Psychiatry, that the term Alzheimer&rsquo;s disease appeared in print for the first time.
Dr Liam Mulcahy, physician trainee and author of&nbsp;Beyond the White Coat, traces that discovery in detail, then Dr Travis Brown turns to two guests for where the disease stands in 2026.
Dr Daniel Clarke, consultant neurologist at Sir Charles Gairdner Hospital and director of clinical trials at Alzheimer&rsquo;s Research Australia, covers how Alzheimer&rsquo;s actually presents (often nothing like the stereotype), why history remains the most important diagnostic tool, and why non-pharmacological measures such as exercise and vascular risk control come before medication. He also explains why family history is often overrated, and why he does not recommend routine APOE4 gene testing.
Dr Gemma Daley, consultant chemical pathologist at Sullivan Nicolaides Pathology, explains what the new p-tau181 and p-tau217 blood tests can and cannot tell a GP, who should and should not be referred for them, and why they are adjunctive tests rather than standalone diagnostic tools.
What to listen for: the presenting features that separate Alzheimer&rsquo;s from ordinary age-related forgetfulness, and what a negative or positive p-tau result actually means for a patient in front of you.
This is the story of Alzheimer&rsquo;s disease.
Useful links:
Dementia Australia:&nbsp;<a href="https://www.dementia.org.au/">https://www.dementia.org.au/</a>
Alzheimer&rsquo;s Research Australia:&nbsp;<a href="https://alzheimersresearch.org.au/">https://alzheimersresearch.org.au/</a>
Our Special Guests:
Dr Liam Mulcahy is a physician trainee with an interest in neurology and author of&nbsp;Beyond the White Coat
Dr Daniel Clarke is a consultant neurologist and director of clinical trials at Alzheimer&rsquo;s Research Australia
Dr Gemma Daley is a consultant chemical pathologist at Sullivan Nicolaides Pathology
Listen:
This Medical Life podcast is available on all podcasting services,&nbsp;<a href="https://podcasts.apple.com/us/podcast/this-medical-life/id1601195297">Apple Podcasts</a>,&nbsp;<a href="https://www.youtube.com/channel/UCOxm-I73JjiBowEMp6JWxSA">YouTube</a>, and&nbsp;<a href="https://open.spotify.com/show/6K8MFiahgDLbYg5uelXS2w">Spotify</a>. Members of the RACGP are able to log the hours as&nbsp;<a href="https://thismedicallife.com.au/cpd-hours/" data-type="page" data-id="437">CPD (Education)</a>&nbsp;that they listen to the episodes under self record via Quick log.&nbsp;<a href="https://thismedicallife.com.au/buy/donation">We invite you to help support us on our donation page</a>.

A 1901 case first identified Alzheimer's disease. Dr Daniel Clarke and Dr Gemma Daley on today's presentation, workup and new blood biomarker tests.

Episode 108: Alzheimer’s Disease | Auguste Deter’s Decline

Two teenage patients, thirty years apart, changed how bone sarcomas are treated. In 1890, seventeen-year-old Bessie Dashiell saw New York surgeon William Coley with a painful hand. Despite an amputation, she died of metastatic cancer ten weeks later. Coley’s search for a better answer led him to Coley’s toxin, a bacterial treatment now recognised as an early form of immunotherapy.

In 1921, pathologist James Ewing treated a fourteen-year-old girl with a wrist tumour he believed was osteosarcoma. Coley’s toxin failed. Radiotherapy, tried next, worked, even though osteosarcoma is classically radiotherapy-resistant. The tumour turned out to be a different disease entirely, now known as Ewing sarcoma, accounting for around 15 percent of bone sarcomas.

Dr Travis Brown traces both stories in detail, then turns to two guests for the clinical picture in 2026.

Dr Liz Connolly, medical oncologist at Peter MacCallum Cancer Centre and oncology research fellow at ProCan Children’s Medical Research Institute, covers staging (localised versus advanced), chemotherapy regimens for osteosarcoma and Ewing sarcoma, targeted therapies, and why immunotherapy has so far shown limited benefit in these cancers. She also discusses five-year survival, which sits around 70 percent for localised osteosarcoma or Ewing sarcoma, and why chondrosarcoma remains difficult to treat with drugs.

Professor Angela Hong, clinical professor at the University of Sydney and radiation oncologist at Royal Prince Alfred Hospital, explains why Ewing sarcoma responds so well to radiotherapy while osteosarcoma and chondrosarcoma do not, how multidisciplinary teams decide between surgery and radiotherapy, current dosing and an active Australian phase III trial, and why early referral to a sarcoma centre matters regardless of where a patient lives.

What to listen for: the diagnostic overlap between early bone sarcoma symptoms and everyday musculoskeletal complaints, and what that means for when to consider imaging and referral.

This is the story of Bone Sarcoma Part 2. Find Part 1 here.

Useful links:

Australia and New Zealand Sarcoma Association: https://sarcoma.org.au/

Find a sarcoma specialist: https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist

Sarcoma guidelines: https://sarcoma.org.au/pages/sarcoma-guidelines

Seeking a second opinion: https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion

Useful patient information: https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information

Our Special Guests:

Dr Liz Connolly is a medical oncologist who specialises in treating and researching sarcomas

Professor Angela Hong is a radiation oncologist and clinical professor at the University of Sydney

Listen:

This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page.

Two teenage patients, thirty years apart, changed how bone sarcomas are treated. In 1890, seventeen-year-old Bessie Dashiell saw New York surgeon William Coley with a painful hand. Despite an amputation, she died of metastatic cancer ten weeks later. Coley&rsquo;s search for a better answer led him to Coley&rsquo;s toxin, a bacterial treatment now recognised as an early form of immunotherapy.
In 1921, pathologist James Ewing treated a fourteen-year-old girl with a wrist tumour he believed was osteosarcoma. Coley&rsquo;s toxin failed. Radiotherapy, tried next, worked, even though osteosarcoma is classically radiotherapy-resistant. The tumour turned out to be a different disease entirely, now known as Ewing sarcoma, accounting for around 15 percent of bone sarcomas.
Dr Travis Brown traces both stories in detail, then turns to two guests for the clinical picture in 2026.
Dr Liz Connolly, medical oncologist at Peter MacCallum Cancer Centre and oncology research fellow at ProCan Children&rsquo;s Medical Research Institute, covers staging (localised versus advanced), chemotherapy regimens for osteosarcoma and Ewing sarcoma, targeted therapies, and why immunotherapy has so far shown limited benefit in these cancers. She also discusses five-year survival, which sits around 70 percent for localised osteosarcoma or Ewing sarcoma, and why chondrosarcoma remains difficult to treat with drugs.
Professor Angela Hong, clinical professor at the University of Sydney and radiation oncologist at Royal Prince Alfred Hospital, explains why Ewing sarcoma responds so well to radiotherapy while osteosarcoma and chondrosarcoma do not, how multidisciplinary teams decide between surgery and radiotherapy, current dosing and an active Australian phase III trial, and why early referral to a sarcoma centre matters regardless of where a patient lives.
What to listen for:&nbsp;the diagnostic overlap between early bone sarcoma symptoms and everyday musculoskeletal complaints, and what that means for when to consider imaging and referral.
This is the story of Bone Sarcoma Part 2.&nbsp;<a href="https://thismedicallife.com.au/episode-106-bone-sarcoma-part-1-osteosarcoma-chondrosaroma-ewing-sarcoma/" data-type="post" data-id="1875">Find Part 1 here</a>.
Useful links:
Australia and New Zealand Sarcoma Association:&nbsp;<a href="https://sarcoma.org.au/">https://sarcoma.org.au/</a>
Find a sarcoma specialist:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist">https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist</a>
Sarcoma guidelines:&nbsp;<a href="https://sarcoma.org.au/pages/sarcoma-guidelines">https://sarcoma.org.au/pages/sarcoma-guidelines</a>
Seeking a second opinion:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion">https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion</a>
Useful patient information:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information">https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information</a>
Our Special Guests:
Dr Liz Connolly is a medical oncologist who specialises in treating and researching sarcomas
Professor Angela Hong is a radiation oncologist and clinical professor at the University of Sydney
Listen:
This Medical Life podcast is available on all podcasting services,&nbsp;<a href="https://podcasts.apple.com/us/podcast/this-medical-life/id1601195297">Apple Podcasts</a>,&nbsp;<a href="https://www.youtube.com/channel/UCOxm-I73JjiBowEMp6JWxSA">YouTube</a>, and&nbsp;<a href="https://open.spotify.com/show/6K8MFiahgDLbYg5uelXS2w">Spotify</a>. Members of the RACGP are able to log the hours as&nbsp;<a href="https://thismedicallife.com.au/cpd-hours/" data-type="page" data-id="437">CPD (Education)</a>&nbsp;that they listen to the episodes under self record via Quick log.&nbsp;<a href="https://thismedicallife.com.au/buy/donation">We invite you to help support us on our donation page</a>.

This is the story of Bone Sarcoma Part 2. Find Part 1 here.

Episode 107: Bone Sarcomas Part 2 | Ewing And Coley’s Legacy

Bone sarcomas are rare, accounting for 0.2% of all cancer diagnoses, with around 200 cases diagnosed in Australia each year. The three main types differ by age and site: osteosarcoma (around 30 to 35% of cases, often in the arms, legs and pelvis, with peaks in adolescence and again in the seventies and eighties), chondrosarcoma (around 30% of cases, typically in adults over 40), and Ewing sarcoma (around 15% of cases, most common in children).

Professor Fiona Maclean, an anatomical pathologist, describes bone sarcoma diagnosis as a pattern-recognition challenge made harder by rarity, noting that tumour type and stage are the two most useful pieces of information for a GP reading a pathology report.

A/Professor Richard Boyle, an orthopaedic oncological surgeon, outlines the red flags, including unexplained deep bone pain and night pain, and the diagnostic pathway from X-ray through biopsy to multidisciplinary review.

This is the story of Bone Sarcoma Part 1.

Useful links:

Australia and New Zealand Sarcoma Association: https://sarcoma.org.au/

Find a sarcoma specialist: https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist

Sarcoma guidelines: https://sarcoma.org.au/pages/sarcoma-guidelines

Seeking a second opinion: https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion

Useful patient information: https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information

Our Special Guests:

A/Professor Richard Boyle who is a Sydney-based orthopaedic oncological surgeon and head of the NSW Sarcoma unit.

Professor Fiona Maclean who is an anatomical pathologist and professor from Macquarie University.

Listen:

This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page.

Bone sarcomas are rare, accounting for 0.2% of all cancer diagnoses, with around 200 cases diagnosed in Australia each year. The three main types differ by age and site: osteosarcoma (around 30 to 35% of cases, often in the arms, legs and pelvis, with peaks in adolescence and again in the seventies and eighties), chondrosarcoma (around 30% of cases, typically in adults over 40), and Ewing sarcoma (around 15% of cases, most common in children).
Professor Fiona Maclean, an anatomical pathologist, describes bone sarcoma diagnosis as a pattern-recognition challenge made harder by rarity, noting that tumour type and stage are the two most useful pieces of information for a GP reading a pathology report.
A/Professor Richard Boyle, an orthopaedic oncological surgeon, outlines the red flags, including unexplained deep bone pain and night pain, and the diagnostic pathway from X-ray through biopsy to multidisciplinary review.
This is the story of Bone Sarcoma Part 1.
Useful links:
Australia and New Zealand Sarcoma Association:&nbsp;<a href="https://sarcoma.org.au/">https://sarcoma.org.au/</a>
Find a sarcoma specialist:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist">https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist</a>
Sarcoma guidelines:&nbsp;<a href="https://sarcoma.org.au/pages/sarcoma-guidelines">https://sarcoma.org.au/pages/sarcoma-guidelines</a>
Seeking a second opinion:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion">https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion</a>
Useful patient information:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information">https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information</a>
Our Special Guests:
A/Professor Richard Boyle who is a Sydney-based orthopaedic oncological surgeon and head of the NSW Sarcoma unit.
Professor Fiona Maclean who is an anatomical pathologist and professor from Macquarie University.
Listen:
This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as&nbsp;<a href="https://thismedicallife.com.au/cpd-hours/" data-type="page" data-id="437">CPD (Education)</a>&nbsp;that they listen to the episodes under self record via Quick log.&nbsp;<a href="https://thismedicallife.com.au/buy/donation">We invite you to help support us on our donation page</a>.

Episode 106: Bone Sarcoma Part 1 | Osteosarcoma, Chondrosaroma & Ewing Sarcoma

The treatment of soft tissue sarcomas is a highly specialised area. The first effective chemotherapy agent against sarcomas was only identified in the 1960s and benefits of adjuvant radiotherapy treatment began in the 1970s. We continue to learn as new agents become available and tailor treatments to each patient.

This is the story of Soft Tissue Sarcoma (Part 2). Here is the link to Part 1.

Useful links:

Australia and New Zealand Sarcoma Association: https://sarcoma.org.au/

Find a sarcoma specialist: https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist

Sarcoma guidelines: https://sarcoma.org.au/pages/sarcoma-guidelines

Seeking a second opinion: https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion

Useful patient information: https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information

Article from the RCPA about reviewing soft tissue tumours and obtaining second opinions: https://pubmed.ncbi.nlm.nih.gov/41390329/

Our Special Guests:

Professor Peter Grimison who is a medical oncologist at Chris O’Brien Lifehouse and clinical professor at University of Sydney

Associate Professor Stephen Thompson is a radiation oncologist at Prince of Wales hospital and conjoint associate professor at the University of New South Wales

The treatment of soft tissue sarcomas is a highly specialised area. The first effective chemotherapy agent against sarcomas was only identified in the 1960s and benefits of adjuvant radiotherapy treatment began in the 1970s. We continue to learn as new agents become available and tailor treatments to each patient.

This is the story of Soft Tissue Sarcoma (Part 2). Here is the link to Part 1.

Useful links:

Australia and New Zealand Sarcoma Association: https://sarcoma.org.au/

Find a sarcoma specialist: https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist

Sarcoma guidelines: https://sarcoma.org.au/pages/sarcoma-guidelines

Seeking a second opinion: https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion

Useful patient information: https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information

Article from the RCPA about reviewing soft tissue tumours and obtaining second opinions: https://pubmed.ncbi.nlm.nih.gov/41390329/

Our Special Guests:

Professor Peter Grimison who is a medical oncologist at Chris O’Brien Lifehouse and clinical professor at University of Sydney

Associate Professor Stephen Thompson is a radiation oncologist at Prince of Wales hospital and conjoint associate professor at the University of New South Wales

Listen:

This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page.

The treatment of soft tissue sarcomas is a highly specialised area. The first effective chemotherapy agent against sarcomas was only identified in the 1960s and benefits of adjuvant radiotherapy treatment began in the 1970s. We continue to learn as new agents become available and tailor treatments to each patient.
This is the story of Soft Tissue Sarcoma (Part 2). Here is the&nbsp;<a href="https://thismedicallife.com.au/episode-104-soft-tissue-sarcoma-part-1-avoiding-the-whoops-lesion/" data-type="post" data-id="1843">link to Part 1</a>.
Useful links:
Australia and New Zealand Sarcoma Association:&nbsp;<a href="https://sarcoma.org.au/">https://sarcoma.org.au/</a>
Find a sarcoma specialist:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist">https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist</a>
Sarcoma guidelines:&nbsp;<a href="https://sarcoma.org.au/pages/sarcoma-guidelines">https://sarcoma.org.au/pages/sarcoma-guidelines</a>
Seeking a second opinion:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion">https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion</a>
Useful patient information:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information">https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information</a>
Article from the RCPA about reviewing soft tissue tumours and obtaining second opinions:&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/41390329/">https://pubmed.ncbi.nlm.nih.gov/41390329/</a>
Our Special Guests:
Professor Peter Grimison who is a medical oncologist at Chris O&rsquo;Brien Lifehouse and clinical professor at University of Sydney
Associate Professor Stephen Thompson is a radiation oncologist at Prince of Wales hospital and conjoint associate professor at the University of New South Wales
The treatment of soft tissue sarcomas is a highly specialised area. The first effective chemotherapy agent against sarcomas was only identified in the 1960s and benefits of adjuvant radiotherapy treatment began in the 1970s. We continue to learn as new agents become available and tailor treatments to each patient.
This is the story of Soft Tissue Sarcoma (Part 2). Here is the&nbsp;<a href="https://thismedicallife.com.au/episode-104-soft-tissue-sarcoma-part-1-avoiding-the-whoops-lesion/" data-type="post" data-id="1843">link to Part 1</a>.
Useful links:
Australia and New Zealand Sarcoma Association:&nbsp;<a href="https://sarcoma.org.au/">https://sarcoma.org.au/</a>
Find a sarcoma specialist:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist">https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist</a>
Sarcoma guidelines:&nbsp;<a href="https://sarcoma.org.au/pages/sarcoma-guidelines">https://sarcoma.org.au/pages/sarcoma-guidelines</a>
Seeking a second opinion:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion">https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion</a>
Useful patient information:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information">https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information</a>
Article from the RCPA about reviewing soft tissue tumours and obtaining second opinions:&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/41390329/">https://pubmed.ncbi.nlm.nih.gov/41390329/</a>
Our Special Guests:
Professor Peter Grimison who is a medical oncologist at Chris O&rsquo;Brien Lifehouse and clinical professor at University of Sydney
Associate Professor Stephen Thompson is a radiation oncologist at Prince of Wales hospital and conjoint associate professor at the University of New South Wales
Listen:
This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as <a href="https://thismedicallife.com.au/cpd-hours/" data-type="page" data-id="437">CPD (Education)</a>&nbsp;that they listen to the episodes under self record via Quick log.&nbsp;<a href="https://thismedicallife.com.au/buy/donation">We invite you to help support us on our donation page</a>.

Episode 105: Soft Tissue Sarcoma Part 2 | Adjuvant Therapies

Soft tissue sarcomas are tumours that arise from connective tissue, fat, muscle, and blood vessels. They are distinct from epithelial malignancies (carcinomas) in both morphology and behaviour. Unfortunately, due to their rare occurrence, these tumours can be mistaken clinically and pathologically which affects patients management and prognosis.

As part of sarcoma awareness month, we are doing a series on soft tissue sarcomas as well as bone sarcoma in conjunction with the Australian & New Zealand Sarcoma Association to raise awareness and help provide education about these diagnoses.

This is the story of soft tissue sarcoma (part 1).

Useful links:

Australia and New Zealand Sarcoma Association: https://sarcoma.org.au/

Find a sarcoma specialist: https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist

Sarcoma guidelines: https://sarcoma.org.au/pages/sarcoma-guidelines

Seeking a second opinion: https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion

Useful patient information: https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information

Article from the RCPA about reviewing soft tissue tumours and obtaining second opinions: https://pubmed.ncbi.nlm.nih.gov/41390329/

Our Special Guests:

Associate Professor Richard Boyle who is an orthopaedic oncologist and surgeon who specialises in the bone and soft tissue sarcoma.

Professor Fiona Maclean is an anatomical pathologist who specialises in soft tissue pathology and clinical professor at Macquarie University.

Listen:

This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page.

Soft tissue sarcomas are tumours that arise from connective tissue, fat, muscle, and blood vessels. They are distinct from epithelial malignancies (carcinomas) in both morphology and behaviour. Unfortunately, due to their rare occurrence, these tumours can be mistaken clinically and pathologically which affects patients management and prognosis.
As part of sarcoma awareness month, we are doing a series on soft tissue sarcomas as well as bone sarcoma in conjunction with the Australian &amp; New Zealand Sarcoma Association to raise awareness and help provide education about these diagnoses.
This is the story of soft tissue sarcoma (part 1).
Useful links:
Australia and New Zealand Sarcoma Association:&nbsp;<a href="https://sarcoma.org.au/">https://sarcoma.org.au/</a>
Find a sarcoma specialist:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist">https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist</a>
Sarcoma guidelines:&nbsp;<a href="https://sarcoma.org.au/pages/sarcoma-guidelines">https://sarcoma.org.au/pages/sarcoma-guidelines</a>
Seeking a second opinion:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion">https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion</a>
Useful patient information:&nbsp;<a href="https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information">https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information</a>
Article from the RCPA about reviewing soft tissue tumours and obtaining second opinions:&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/41390329/">https://pubmed.ncbi.nlm.nih.gov/41390329/</a>
Our Special Guests:
Associate Professor Richard Boyle who is an orthopaedic oncologist and surgeon who specialises in the bone and soft tissue sarcoma.
Professor Fiona Maclean is an anatomical pathologist who specialises in soft tissue pathology and clinical professor at Macquarie University.
Listen:
This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as&nbsp;<a href="https://thismedicallife.com.au/cpd-hours/" data-type="page" data-id="437">CPD (Education)</a>&nbsp;that they listen to the episodes under self record via Quick log.&nbsp;<a href="https://thismedicallife.com.au/buy/donation">We invite you to help support us on our donation page</a>.

Episode 104: Soft Tissue Sarcoma Part 1 | Avoiding The Whoops Lesion

Welcome to the This Medical Life podcast. Our mission is to share stories about the triumphs and tragedies of diseases and illnesses from ancient times up until what we know today. It is about those scientific and medical minds who came before us and how, every single day, we stand on the shoulders of giants. This is a podcast about the stories of medicine. Hosted by Dr. Travis Brown and Steve Davis, our target audience is General Practitioners, medical students, and other health professionals. We hope to educate, inspire and celebrate those who choose to care for others in their profession. From experience, we know that our audience extends beyond these fields and would like to welcome anyone to listen. The stories of those who came before us are nothing short of remarkable and we hope you enjoy them as much as we do. Production by Steve Davis

Welcome to the This Medical Life podcast. Our mission is to share stories about the triumphs and tragedies of diseases and illnesses from ancient times up until what we know today. It is about those scientific and medical minds who came before us and how, every single day, we stand on the shoulders of giants. This is a podcast about the stories of medicine. Hosted by Dr. Travis Brown and Steve Davis, our target audience is General Practitioners, medical students, and other health professionals. We hope to educate, inspire and celebrate those who choose to care for others in their profession. From experience, we know that our audience extends beyond these fields and would like to welcome anyone to listen. The stories of those who came before us are nothing short of remarkable and we hope you enjoy them as much as we do. Production by Steve Davis

This Medical Life

Welcome to the This Medical Life podcast. Our mission is to share stories about the triumphs and tragedies of diseases and illnesses from ancient times up until what we know today. It is about those scientific and medical minds who came before us and how, every single day, we stand on the shoulders of giants. This is a podcast about the stories of medicine.


Hosted by Dr. Travis Brown and Steve Davis, our target audience is General Practitioners, medical students, and other health professionals. We hope to educate, inspire and celebrate those who choose to care for others in their profession. From experience, we know that our audience extends beyond these fields and would like to welcome anyone to listen. The stories of those who came before us are nothing short of remarkable and we hope you enjoy them as much as we do.

Production by Tim Whiffen

Design by Tom Buzz

This Medical Life

Social links:

Follow the podcast:

157 clip(s)